Baker Brothers portfolio, Q4 2024

Baker Bros. Advisors · 13F for the quarter ending Dec 31, 2024

For Q4 2024, Baker Bros. Advisors reported $9.4B across 95 US-listed positions, led by INCY (22.7%), ONC (18.8%) and ACAD (8.4%). Compared with its filing for Q3 2024, Baker Brothers opened 9 new positions, added to 20, reduced 4 and sold out of 7; 61 positions did not change.

The largest purchase was an addition to INSM ($40.8M); the largest sale, a reduction of ONC ($191.5M).

Reported value
$9.4B
Positions
95
In the top 10
77%
Filed
Feb 14
2025

Key facts

13F portfolio value
$9.4BQ4 2024
Positions
95
Largest holding
INCY 22.7%
New positions
9
Sold out
7
Filed
Feb 14, 2025

Holdings as of (Q4 2024), filed with the SEC on . Changes are measured against the filing for Sep 30, 2024. Every tracked investor's Q4 2024 13F.

Bought and sold in Q4 2024

Baker Brothers: buys and sells in Q4 2024
StockMoveSharesSizeOf portfolio
Beone Medicines LtdONC▼ Reduced 9.8%−1.04M$191.5M2.05%
Insmed IncINSM▲ Added 13%+590.95K$40.8M0.44%
Ionis Pharmaceuticals Incno ticker on file
▲ New—$29.5M0.32%
Grail IncGRAL▲ New+1.63M$29.1M0.31%
Candel Therapeutics IncCADL▲ New+2.98M$25.9M0.28%
Bicycle Therapeutics PlcBCYC▲ Added 16%+1.49M$20.8M0.22%
CRISPR Therapeutics AGCRSP▲ Added 55%+464.94K$18.3M0.20%
Rhythm Pharmaceuticals IncRYTM▼ Reduced 4.9%−314.12K$17.6M0.19%
Revolution Medicines IncRVMD▲ Added 4.9%+367.88K$16.1M0.17%
Immunovant IncIMVT▲ Added 39%+482.47K$12M0.13%
Roivant Sciences LtdROIV▲ Added 35%+969.06K$11.5M0.12%
Celcuity IncCELC▲ Added 43%+803.58K$10.5M0.11%
Edgewise Therapeutics IncEWTX▲ Added 5.4%+315.88K$8.4M0.09%
Vir Biotechnology IncVIR▲ New+1.08M$8M0.09%
Intellia Therapeutics IncNTLA▲ New+644.12K$7.5M0.08%
Structure Therapeutics IncGPCR▲ Added 323%+276.07K$7.5M0.08%
Merus N Vno ticker on file
▲ Added 50%+150K$6.3M0.07%
Immatics N.V.IMTX▲ Added 13%+832.43K$5.9M0.06%
Tango Therapeutics IncTNGX▼ Sold out−750K$5.8M0.06%
Crinetics Pharmaceuticalsno ticker on file
▼ Sold out−103.93K$5.3M0.06%
BioNTech SEBNTX▲ New+45.03K$5.1M0.05%
Neurogene IncNGNE▲ Added 48%+218.44K$5M0.05%
Disc Medicine IncIRON▲ New+77.05K$4.9M0.05%
Ionis Pharmaceuticals IncIONS▲ Added 60%+134.45K$4.7M0.05%
Alector IncALEC▼ Sold out−927.26K$4.3M0.05%
Stoke Therapeutics IncSTOK▲ Added 6.1%+265.4K$2.9M0.03%
Biomea Fusion IncBMEA▼ Reduced 31%−656.96K$2.5M0.03%
KALA BIO IncKALA▲ Added 35%+310.56K$2.2M0.02%
Sagimet Biosciences IncSGMT▼ Reduced 31%−428.9K$1.9M0.02%
Newamsterdam Pharma CompanyNAMS▼ Sold out−96.71K$1.6M0.02%
Aerovate Therapeutics Incno ticker on file
▼ Sold out−628.94K$1.3M0.01%
Rocket Pharmaceuticals IncRCKT▲ New+97.08K$1.2M0.01%
Pfizer IncPFE▼ Sold out−35K$1M0.01%
PTC Therapeutics IncPTCT▲ New+20.4K$920.9K0.01%
Praxis Precision MedicinesPRAX▲ Added 2.6%+8.43K$648.6K0.01%
BioCryst Pharmaceuticals IncBCRX▼ Sold out−75.78K$575.9K0.01%
Fate Therapeutics IncFATE▲ Added 8.7%+260.63K$430K0.00%
Skye Bioscience IncSKYE▲ Added 1.1%+16K$45.3K0.00%
Incyte CorpINCY▲ Added 0.00%+446$30.8K0.00%
IGM Biosciences Incno ticker on file
▲ Added 0.05%+1.99K$12.2K0.00%

Holdings at the quarter's end

Baker Brothers holdings, Q4 2024
#StockSectorShare of portfolioValueSharesReported priceHeldSince Q3 2024
1Incyte CorpINCYHealth Care22.7%$2.1B30.74M$69.073+ qtrs▲ Added 0.00%
2Beone Medicines LtdONC · SPONSORED ADSHealth Care18.8%$1.8B9.53M$184.713+ qtrs▼ Reduced 9.8%
3Acadia Pharmaceuticals IncACAD—8.41%$786.8M42.88M$18.353+ qtrsNo change
4Madrigal Pharmaceuticals IncMDGLHealth Care6.51%$609.3M1.97M$308.573+ qtrsNo change
5Summit Therapeutics IncSMMTHealth Care4.66%$435.9M24.42M$17.853+ qtrsNo change
6Revolution Medicines IncRVMDHealth Care3.71%$347.2M7.94M$43.743+ qtrs▲ Added 4.9%
7Insmed IncINSMHealth Care3.69%$345.7M5.01M$69.043+ qtrs▲ Added 13%
8Rhythm Pharmaceuticals IncRYTMHealth Care3.64%$340.6M6.08M$55.983+ qtrs▼ Reduced 4.9%
9Kymera Therapeutics IncKYMRHealth Care2.58%$241.2M6M$40.233+ qtrsNo change
10Kodiak Sciences IncKODHealth Care1.84%$172.2M17.31M$9.953+ qtrsNo change
11Edgewise Therapeutics IncEWTXHealth Care1.76%$164.4M6.16M$26.703+ qtrs▲ Added 5.4%
12Bicycle Therapeutics PlcBCYC · SPONSORED ADS—1.63%$152.4M10.89M$14.003+ qtrs▲ Added 16%
13Replimune Group IncREPL—1.43%$133.8M11.05M$12.113+ qtrsNo change
14Alkermes PLCALKS · SHSHealth Care1.29%$120.3M4.18M$28.763+ qtrsNo change
15
Insmed Incno ticker on file · NOTE 0.75% 6/1/2028
—0.99%$92.9M——3+ qtrsNo change
16Entrada Therapeutics IncTRDA—0.90%$84.1M4.87M$17.293+ qtrsNo change
17Abcellera Biologics IncABCL—0.86%$80.7M27.53M$2.933+ qtrsNo change
18Denali Therapeutics IncDNLI—0.81%$76.1M3.73M$20.383+ qtrsNo change
19Nurix Therapeutics IncNRIX—0.78%$73.1M3.88M$18.843+ qtrsNo change
20argenx SEARGX · SPONSORED ADRHealth Care0.74%$68.8M111.9K$615.003+ qtrsNo change
21Ultragenyx PharmaceuticalRARE—0.71%$66.3M1.58M$42.073+ qtrsNo change
22Kiniksa Pharmaceuticals InternationalKNSA · ORD SHS CL AHealth Care0.60%$55.7M2.82M$19.783+ qtrsNo change
23Immatics N.V.IMTX · SHS—0.55%$51.7M7.28M$7.113+ qtrs▲ Added 13%
24CRISPR Therapeutics AGCRSP · NAMEN AKTHealth Care0.55%$51.5M1.31M$39.363+ qtrs▲ Added 55%
25Stoke Therapeutics IncSTOK—0.55%$51.1M4.63M$11.033+ qtrs▲ Added 6.1%
26Immunocore Holdings plcIMCR · ADS—0.48%$44.7M1.52M$29.503+ qtrsNo change
27Roivant Sciences LtdROIV · SHSHealth Care0.48%$44.6M3.77M$11.833+ qtrs▲ Added 35%
28Sera Prognostics IncSERA · CLASS A COM—0.47%$44.2M5.43M$8.143+ qtrsNo change
29Immunovant IncIMVTHealth Care0.45%$42.3M1.71M$24.773+ qtrs▲ Added 39%
30Xenon Pharmaceuticals IncXENE—0.42%$39M993.68K$39.203+ qtrsNo change
31Celcuity IncCELC—0.38%$35.1M2.68M$13.093+ qtrs▲ Added 43%
32Monte Rosa Therapeutics IncGLUE—0.36%$34.1M4.92M$6.943+ qtrsNo change
33
Akero Therapeutics Incno ticker on file
—0.33%$30.5M1.1M$27.823+ qtrsNo change
34Cerus CorpCERS—0.32%$30M19.48M$1.543+ qtrsNo change
35
Ionis Pharmaceuticals Incno ticker on file · NOTE 1.75% 6/15/2028
—0.32%$29.5M——1 qtrNew
36Grail IncGRALHealth Care0.31%$29.1M1.63M$17.851 qtrNew
37IDEAYA Biosciences IncIDYA—0.29%$27.3M1.06M$25.703+ qtrsNo change
38Krystal Biotech IncKRYSHealth Care0.28%$26.6M169.93K$156.663+ qtrsNo change
39Candel Therapeutics IncCADL—0.28%$25.9M2.98M$8.681 qtrNew
40Praxis Precision MedicinesPRAXHealth Care0.27%$25.5M331.53K$76.963+ qtrs▲ Added 2.6%
41
IGM Biosciences Incno ticker on file
—0.27%$25M4.09M$6.113+ qtrs▲ Added 0.05%
42
Centessa Pharmaceuticals PLCno ticker on file · SPONSORED ADS
—0.22%$20.6M1.23M$16.753+ qtrsNo change
43
Merus N Vno ticker on file
—0.20%$18.9M450K$42.053+ qtrs▲ Added 50%
44Dyne Therapeutics IncDYN—0.17%$15.8M672.1K$23.563+ qtrsNo change
45Neurogene IncNGNE—0.17%$15.4M674.45K$22.863+ qtrs▲ Added 48%
46Xencor IncXNCR—0.17%$15.4M670.43K$22.983+ qtrsNo change
47Bicara Therapeutics IncBCAX—0.16%$14.5M833.33K$17.422 qtrsNo change
48Prelude Therapeutics IncPRLD—0.14%$12.9M10.12M$1.283+ qtrsNo change
49Ionis Pharmaceuticals IncIONSHealth Care0.13%$12.5M357.92K$34.962 qtrs▲ Added 60%
50Alumis IncALMS—0.13%$12.3M1.56M$7.863+ qtrsNo change
51Neumora Therapeutics IncNMRA—0.12%$11M1.03M$10.603+ qtrsNo change
52Design Therapeutics IncDSGN—0.12%$10.8M1.74M$6.173+ qtrsNo change
53Structure Therapeutics IncGPCR · SPONSORED ADS—0.11%$9.8M361.57K$27.122 qtrs▲ Added 323%
54
Verve Therapeutics Incno ticker on file
—0.10%$9.5M1.69M$5.643+ qtrsNo change
55
Opthea Limitedno ticker on file · SPONSORED ADS
—0.09%$8.5M2.17M$3.933+ qtrsNo change
56TScan Therapeutics IncTCRX—0.09%$8.5M2.78M$3.043+ qtrsNo change
57KALA BIO IncKALA—0.09%$8.3M1.2M$6.943+ qtrs▲ Added 35%
58Vir Biotechnology IncVIR—0.09%$8M1.08M$7.341 qtrNew
59Mirum Pharmaceuticals IncMIRMHealth Care0.08%$7.9M190.48K$41.353+ qtrsNo change
60Arvinas IncARVN—0.08%$7.8M405.58K$19.172 qtrsNo change
61Intellia Therapeutics IncNTLA—0.08%$7.5M644.12K$11.661 qtrNew
62
2seventy bio Incno ticker on file
—0.08%$7.3M2.5M$2.943+ qtrsNo change
63Taysha Gene Therapies IncTSHA—0.07%$6.9M4M$1.733+ qtrsNo change
64Celldex Therapeutics IncCLDX—0.07%$6.3M247.64K$25.273+ qtrsNo change
65Biomea Fusion IncBMEA—0.06%$5.6M1.45M$3.883+ qtrs▼ Reduced 31%
66Fate Therapeutics IncFATE—0.06%$5.4M3.26M$1.653+ qtrs▲ Added 8.7%
67BioNTech SEBNTX · SPONSORED ADSHealth Care0.06%$5.1M45.03K$113.951 qtrNew
68Disc Medicine IncIRON—0.05%$4.9M77.05K$63.401 qtrNew
69Relay Therapeutics IncRLAY—0.05%$4.8M1.16M$4.123+ qtrsNo change
70Contineum Therapeutics IncCTNM · CL A—0.05%$4.6M312.5K$14.653+ qtrsNo change
71Dbv Technologies S A SponsoredDBVT · SPONSORED ADS—0.05%$4.5M1.46M$3.093+ qtrs—
72Sagimet Biosciences IncSGMT—0.05%$4.3M953K$4.503+ qtrs▼ Reduced 31%
73Wave Life Sciences LtdWVE · SHS—0.05%$4.3M344.06K$12.372 qtrsNo change
74Skye Bioscience IncSKYE—0.04%$4.1M1.45M$2.833+ qtrs▲ Added 1.1%
75Vaxcyte IncPCVXHealth Care0.04%$4M48.89K$81.863+ qtrsNo change
76Sana Biotechnology IncSANA—0.04%$3.9M2.38M$1.633+ qtrsNo change
77
Leap Therapeutics Incno ticker on file
—0.04%$3.4M1.17M$2.873+ qtrsNo change
78Aligos Therapeutics IncALGS—0.04%$3.3M83.06K$39.843+ qtrsNo change
79Prime Medicine IncPRME—0.03%$3M1.03M$2.923+ qtrsNo change
80Protara Therapeutics IncTARA—0.03%$2.8M536.83K$5.283+ qtrsNo change
81Enliven Therapeutics IncELVN—0.03%$2.6M114.83K$22.503+ qtrsNo change
82Arcturus Therapeutics HoldingsARCT—0.03%$2.6M151.33K$16.973+ qtrsNo change
83Compass Therapeutics IncCMPX—0.02%$2.3M1.56M$1.453+ qtrsNo change
84
Generation Bio Cono ticker on file
—0.02%$2.1M1.94M$1.063+ qtrsNo change
85
HOOKIPA Pharma Incno ticker on file
—0.02%$1.6M812.81K$2.013+ qtrsNo change
86
Mersana Therapeutics Incno ticker on file
—0.02%$1.6M1.09M$1.433+ qtrsNo change
87vTv Therapeutics IncVTVT · CL A—0.01%$1.3M97.31K$13.813+ qtrsNo change
88Rocket Pharmaceuticals IncRCKT—0.01%$1.2M97.08K$12.571 qtrNew
89PTC Therapeutics IncPTCTHealth Care0.01%$920.9K20.4K$45.141 qtrNew
90Century Therapeutics IncIPSC—0.01%$805.4K797.46K$1.013+ qtrsNo change
91PMV Pharmaceuticals IncPMVP—0.01%$486.3K322.02K$1.513+ qtrsNo change
92Acrivon Therapeutics IncACRV—0.00%$318.4K52.89K$6.023+ qtrsNo change
93Foghorn Therapeutics IncFHTX—0.00%$212.5K45.03K$4.723+ qtrsNo change
94Tyra Biosciences IncTYRA—0.00%$147.4K10.61K$13.903+ qtrsNo change
95
Surrozen Incno ticker on file · W EXP 8/11/2026
—0.00%$17.8K833.33K$0.02143+ qtrsNo change

By sector

Baker Brothers portfolio by sector, Q4 2024
SectorShare of portfolioValuePositions
Health Care75.1%$7B24
No sector on file24.9%$2.3B71

Questions and answers

What did Baker Brothers own in Q4 2024?

Baker Bros. Advisors's 13F for Q4 2024 lists 95 positions worth $9.4B. The largest: INCY (22.7%), ONC (18.8%), ACAD (8.4%), MDGL (6.5%), SMMT (4.7%).

What did Baker Brothers buy in Q4 2024?

The largest purchases, by the shares bought at the quarter-end price the filing implies: INSM (added, $40.8M), Ionis Pharmaceuticals Inc (new, $29.5M), GRAL (new, $29.1M), CADL (new, $25.9M), BCYC (added, $20.8M), CRSP (added, $18.3M).

What did Baker Brothers sell in Q4 2024?

The largest sales: ONC (reduced, $191.5M), RYTM (reduced, $17.6M), TNGX (sold out, $5.8M), Crinetics Pharmaceuticals (sold out, $5.3M), ALEC (sold out, $4.3M), BMEA (reduced, $2.5M).

When was this filing made?

Baker Bros. Advisors filed its 13F for the quarter ending Dec 31, 2024 on Feb 14, 2025. A 13F is due within 45 days of the quarter's end, so the positions were already weeks old when it became public.

Learn

Cite this page

Funkfolio, “Baker Brothers portfolio, Q4 2024: Baker Bros. Advisors 13F holdings”, data as of 14 February 2025. https://funkfolio.com/gurus/baker-brothers/2024-q4

Underlying data: SEC EDGAR, Form 13F-HR of Baker Bros. Advisors (CIK 1263508) for the period ending Dec 31, 2024.

Source: SEC EDGAR, Form 13F-HR for Baker Bros. Advisors (CIK 1263508), period ending Dec 31, 2024, filed Feb 14, 2025. Changes compare share counts with the filing for Sep 30, 2024; a share split in between is allowed for where one is on record. “Reported price” is a position's reported value divided by its shares. The size of a buy or sell is the change in shares at that price; a position sold out is sized at its value in the previous filing, and “of portfolio” sets the size against the $9.4B reported for this quarter. “Held” counts consecutive quarterly filings up to this one, out of the 3 looked at from here back. Sectors are those of the ranked companies on this site as they stand today. Not a live portfolio and not advice.